Agenus pointing to its checkpoint inhibitors

Agenus Inc. (NASDAQ:AGEN) is looking past the demise of its Prophage G-200 vaccine in brain cancer and pointing investors to upcoming milestones for its checkpoint inhibitor combinations.

The company’s shares fell 16% on Wednesday after it disclosed it had halted accrual of patients in a Phase II trial combining its Prophage G-200 with Avastin bevacizumab after a DSMB concluded the study was unlikely to improve survival compared to Avastin alone in surgically resectable, recurrent glioblastoma multiforme...